Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. März 2024 08:00 ET | Quelle: Frontier Medicines

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance...
27. Februar 2024 08:00 ET | Quelle: Frontier Medicines

Frontier Medicines to Participate in Upcoming Investor Conferences

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
22. Februar 2024 16:01 ET | Quelle: Frontier Medicines

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Frontier Medicines Series C close and first patient dosed
03. Januar 2024 07:00 ET | Quelle: Frontier Medicines

Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
08. Mai 2023 08:00 ET | Quelle: Frontier Medicines

Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer

BOSTON and SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
16. April 2023 15:00 ET | Quelle: Frontier Medicines

Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting

-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of KRASG12C and overcome the limitations seen with single-acting...
14. März 2023 17:56 ET | Quelle: Frontier Medicines

Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting

BOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
28. Februar 2023 08:00 ET | Quelle: Frontier Medicines

Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
05. Januar 2023 07:30 ET | Quelle: Frontier Medicines

Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies

FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome non-response and resistance seen with prior generation KRASG12C inhibitors The company has...
05. Januar 2023 07:00 ET | Quelle: Frontier Medicines

Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie

SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against...

Vorherige Seite

Nächste Seite